It has been reported that there are stem-like cells in tumors as well as in normal tissue. In some tumors, they are defined as tumor initiating cells because they can induce tumorigenesis in nude mice. The tumor stem cell hypothesis states that only a rare, phenotypically distinct subset of cells act as tumor stem cells (sometimes called tumor initiating cells), which not only possess unlimited proliferation potential but also the capability for self-renewal, asymmetric division, multi-line differentiation and the formation of a new tumor, [1] [2] [3] [4] and they are responsible for the refractoriness and recurrence of tumors. Therefore, the isolation and research of the 'tumor initiating cell' appears very important in understanding tumorigenesis and subsequently in developing treatment strategies. 5) Human CD133/prominin-1 is used as a useful marker for identification and isolation of many tumor stem cells, such as brain, [6] [7] [8] breast, 9) prostate, 10) lung, 11, 12) liver 13, 14) and pancreas 14, 15) cancers et al. In 2007, O'Brien et al. and Ricci-Vitiani et al. proved in vivo that CD133 is expressed in human colorectal carcinomas, and the colon cancer-initiating cells (CC-ICs) are almost exclusively a small fraction of CD133ϩ cells. 16, 17) This preponderance of CD133ϩ cells seems to confirm that they are tumorigenic and able to contribute to disease progression. Yet, in 2008 a study performed by Shmelkov et al. challenged this increasingly influential opinion. 18) Firstly, they overthrew the opinion that CD133 is restrictedly distributed in a small cell population. CD133 is widely expressed on all malignant epithelial cells in the primary human and murine colon tumors. Secondly, they found that not only CD133ϩ cells, but also CD133Ϫ cells can generate tumors in nude mice. Thereby they thought that CD133 negative cells in O'Brien and Ricci-Vitiani's studies primarily consist of nontumorigenic stromal and inflammatory cells incapable of tumor initiation. Thirdly, they proved that CD133 negative cells correlate with the ability of colon tumors to metastasize. The CD133 negative subset originates from CD133ϩ cells and results in the formation of more aggressive growing tumors. 18) Aside from this research, several other studies have also shown that both CD133(ϩ) and CD133(Ϫ) subpopulations of some cell lines contain cancerinitiating cells. [19] [20] [21] Moreover, Clement's findings showed that neither the expression of stemness genes nor the longterm self-renewal capacities of CD133(ϩ) and CD133(Ϫ) cells were significantly different. 22) Faced with contrasting opinions, how can we ascertain the status of CD133ϩ cells in tumor cells? Is there any other relationship between CD133 expression and tumor stem cell characteristics?
Though both CD133 positive and CD133 negative subsets can serially induce tumorigenesis in nude mice as Shmelkov found, it appears that there must be some unknown tumor stem cell markers functioning other than CD133. As CD133 is found to be a marker of many kinds of tumor stem cells, we assume that CD133 is undoubtedly an important marker for active tumor stem cells, and the abundance of CD133 expressed on tumor cells might be more important in reflecting the features of active tumor stem cells. This might be the reason behind the difference between the two aforementioned opinions.
To further support this assumption, we performed some experiments on colorectal tumor cell line SW620 to compare the in vitro and in vivo biological features of tumor subsets with different CD133 expression. As the tumor cells are only identified as two subsets using FACs (fluorescence activated cell sorting), CD133 positive and CD133 negative, we chose to isolate tumor cells into three subgroups using MACs (magnetic activated cell sorting). 
MATERIALS AND METHODS
SW620 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). They were then sorted and enriched using the Miltenyi indirect magnetic labeling system according to the manufacturer's protocol (www.Miltenyibiotec.com). The cells were isolated into positive (A) and negative (B) groups at the first filtration. Then the positive cells (A) were isolated for the second time to get CD133 double-positive cells (on the column). The negative cells (B) in the first filtration were isolated for the second time to get CD133 double-negative cells (off the column). The remaining cells, including both the groups of twice infiltrated cells other than CD133 doublepositive cells and CD133 double-negative cells were mixed to compose CD133ϩ cells. Then the sorted CD133ϩϩ, CD133ϩ and CD133ϪϪ cells were regarded as CD133
Hi , CD133
Mid and CD133 Low subsets and re-suspended in DMEM supplemented with 10% FBS for experiments described below.
After isolation, CD133 Hi , CD133
Mid , CD133 Low and unsorted tumor cells were assessed for purity of CD133 positive cells by Flow Cytometry and then respectively cultured in tissue culture dishes. On passage 0, 2 and 4, the tumor cells were respectively studied in vitro and in vivo. In vitro, the abundance of surface antigen CD133 in each subgroup was detected to estimate the CD133 expression level on different passages by Western blot. The immunoreactive bands were scanned and quantified using Gel-Pro software. Then the data was used to draw curves of CD133 protein expression. At the same time, a portion of cells were seeded in 6-well plates at a cell density of 10 4 cells per well in triplicates. Cells were counted at day 10 and observed for growth pattern. In vivo, 2ϫ10 6 tumor cells of each subgroup were transplanted subcutaneously (s.c.) into nude mice. The volumes of tumor masses were measured every five days for six weeks. Then the growth curves were drawn according to the data to assess the relationship between CD133 expression and tumor growth rate.
Statistical Methods Statistical analysis was performed using SPSS for Windows version 11.5. Analysis of ANOVA was used when more than two groups were compared. Data is presented as meanϮS.D. The values pϽ0.05 were considered significant.
RESULTS
The in vitro results show that the CD133 expressions in different subsets were obviously distinct (Fig. 1) . The CD133 expression levels were obviously different among the three subsets (a) with the highest expression of CD133 in CD133 Hi subgroup and the lowest in CD133
Low subgroup. The CD133 expressions in CD133
Hi and CD133 Mid subsets decreased as the cells were passaged, whereas it increased in CD133 Low subgroup compared with passage 0 (b). In the assays of CD133ϩ purity in each subgroup, the CD133
Hi subgroup can reach 95.6% in purity (Fig. 2) . This provides us proper conditions to further quantitatively compare the features of tumor stem cells.
The plating efficiency test showed that the growing patterns of the cells in different subgroups are different (Fig. 3) . The clonogenic ability of CD133
Hi cells reflects the characteristics of powerful self-renewal.
The in vivo results show that the CD133 Hi cells grew faster than CD133
Mid and CD133 Low cells in different passages, but After isolation, the purified cells were analyzed by Flow Cytometry. The purity of CD133 positive SW620 cells reached 95.6% in CD133 Hi subgroup. In this area plot, the white area represents staining with CD133 mAb, and the grey peak represents the isotype control-matched mAb.
the difference reduced in the later passages. The in vivo tumor growth rate clearly correlated to the level of CD133 expression in early passages. On the whole, the CD133 Hi subgroup showed the highest growth rate and the CD133 Low subgroup showed the lowest. But the CD133 Low subset did not lose the tumorigenicity in nude mice although they grew slowest among the three subsets (Fig. 4) .
Gross and microscopic observations show the differing self-renewal abilities of the tumor cells (Fig. 5) . The in vivo tumor growth rates are not consistent among all subsets. The CD133 Hi tumors grew faster than the other groups.
DISCUSSION
In the studies performed by O'Brien and Ricci, the expression of CD133 was assessed by Flow Cytometry after isolating the CD133ϩ cells, and they drew the conclusions that tumor stem cells existed in CD133 positive cells, yet the CD133 negative cells comprising the majority of the tumor were unable to initiate tumor growth. Using Il10-/-CD133lacZ mice, Shmelkov et al. reported that CD133 is widely expressed on a full gamut of colonic tumor cells, including all malignant epithelial cells in the primary human and murine colon tumors, whereas the CD133 negative population in primary tumors as O'Brien and Ricci used is mostly likely to be composed of stromal and inflammatory cells. Only in metastatic tumors can real CD133 negative cells be found, which are more aggressive in tumor growth. Here, we considered that since the methods they used are different, the rate of identifying CD133 positive cells is accordingly different. The CD133ϩ expression rate is 100% 18) by LacZ gene b-galactosidase test and 1.8-29% 16, 17) by Flow Cytometry respectively, showing that the LacZ gene b-galactosidase test can comprehensively identify the cells with CD133 expression, which is more sensitive in detecting CD133 expression than Flow Cytometry. The latter is dependent on the fluores- Hi and CD133 Low . Thus, more detailed quantification analyses of CD133 expression are necessary to make the results more convincing.
In our experiment, the cells of CD133 Hi subset in tumor cell line SW620 displayed a higher growth rate than the other subsets when transplanted on nude mice. This indicates that CD133
Hi subgroup is more active in propagating, showing that CD133
Hi cells are more likely to be related to tumor stem cells. The results support the assertion that CD133 positive tumor cells possess characteristics of tumor initiating cells. But the CD133 Low subgroup still possesses the ability of tumorigenesis, although the growth rate is lower than that of CD133 Hi or CD133 Mid cells. The tumorigenicity in all the subsets of CD133 Hi , CD133
Mid and CD133 Low supported that CD133 expression may be relevant to features of tumor stem cell but may not be a specific marker of it. As the result shows, CD133
Low cells were also found to have comparatively weaker reproductive activity. They did not completely lose the ability to self- renew and proliferate. This is inclined to be consistent with some other research in which the absence of CD133 expression might be a feature of slow-cycling or dormant stem cells. 20) In other words, some tumor initiating cells still exist in CD133
Low cells. Therefore, we discreetly infer that tumor stem cells are correlated to the abundance of CD133 expression but not characterized by qualitative expression of CD133. CD133 is not an exclusive marker of colorectal cancer initiating cells. There might be other specific co-expression molecular markers of tumor initiating cells that need to be sought. A combination of CD133 and other markers to search for tumor initiating cells will be more efficient.
CD133 positive cells also exhibited a differentiation trend in vitro as the results show, in which the expression of CD133 decreased gradually in the differentiating process. It is reported that the expression of CD133 in some human tumors may be explained by the theory that the glycosylation of CD133 protein may change depending on the differentiation states of these malignant cells. The higher the cell differentiation, the more down-regulated the CD133 epitope is. 23, 24) Observations indicate that there is hierarchical organization from the initiating cell to the final mature cell, in which CD133 positive fraction might represent an active state of tumor initiating cells, and the CD133 negative fraction might stand for the differentiated or dormant state of tumor stem cells. The existence of a certain proportion of CD133 negative cells may modulate tumor growing in equilibrium by a feedback to keep the proportion of CD133 positive subgroups stable. The detailed modulating mechanism awaits further study. Taking Shmelkov's study into account, the CD133 negative cells might contain a phenotypically anaplastic subset that is found in the metastatic tumors. But this needs to be further proven.
In summary, we discreetly draw the conclusion that tumor stem cell characteristics are more related to CD133 expression level. The CD133
Hi might be a better index to identify and study tumor stem cells. Thus CD133, previously termed tumor stem cell marker, should be described as CD133 To verify whether our hypothesis holds true, more detailed quantitative analyses of CD133 expression is required. In addition, the real CD133 negative cells, not CD133
Low cells, need to be studied on their capability of aggressiveness and metastasis to seek more suitable tumor stem cell markers.
Although our findings confirm the usefulness of quantitatively studying CD133 expression on tumor stem cells in tumor cell line SW620, we need to confirm that this conclusion applies to other tumor cell lines. We should also realize that the research performed on tumor cell lines needs to be verified to be consistent with primary tumors.
